- Home
- PROK vs TNYA Comparison
PROK vs TNYA Comparison
Compare PROK & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- TNYA
- Stock Information
- Founded
- PROK 2015
- TNYA 2016
- Country
- PROK United States
- TNYA United States
- Employees
- PROK N/A
- TNYA N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- PROK Health Care
- TNYA Health Care
- Exchange
- PROK Nasdaq
- TNYA Nasdaq
- Market Cap
- PROK 85.5M
- TNYA 73.8M
- IPO Year
- PROK N/A
- TNYA 2021
- Fundamental
- Price
- PROK $0.58
- TNYA $0.60
- Analyst Decision
- PROK Hold
- TNYA Strong Buy
- Analyst Count
- PROK 3
- TNYA 5
- Target Price
- PROK $3.50
- TNYA $8.60
- AVG Volume (30 Days)
- PROK 1.6M
- TNYA 3.0M
- Earning Date
- PROK 08-08-2025
- TNYA 08-07-2025
- Dividend Yield
- PROK N/A
- TNYA N/A
- EPS Growth
- PROK N/A
- TNYA N/A
- EPS
- PROK N/A
- TNYA N/A
- Revenue
- PROK $306,000.00
- TNYA N/A
- Revenue This Year
- PROK $54.34
- TNYA N/A
- Revenue Next Year
- PROK N/A
- TNYA N/A
- P/E Ratio
- PROK N/A
- TNYA N/A
- Revenue Growth
- PROK N/A
- TNYA N/A
- 52 Week Low
- PROK $0.46
- TNYA $0.36
- 52 Week High
- PROK $2.59
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- PROK 39.26
- TNYA 52.95
- Support Level
- PROK $0.54
- TNYA $0.54
- Resistance Level
- PROK $0.90
- TNYA $0.70
- Average True Range (ATR)
- PROK 0.13
- TNYA 0.06
- MACD
- PROK -0.02
- TNYA -0.00
- Stochastic Oscillator
- PROK 9.55
- TNYA 40.74
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.